RxDoctor Payments Data

Alisha White, MD

Internal Medicine · Saint Louis, MONPI 1467600155

Payments from drug & device makers

$856in general payments, 2019–2025

Across 55 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$395
  • Lilly USA, LLC$165
  • Novo Nordisk$107
  • Amgen$105
  • Biohaven Pharmaceuticals, Inc.$24
  • Astellas Pharma US Inc$18
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$856100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$856 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$41,557
Medicare patients
88
Services billed
431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$50,357
EliquisApixaban31$31,029
XareltoRivaroxaban16$17,391
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen77$1,930
Albuterol Sulfate HfaAlbuterol Sulfate75$1,761
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen40$1,491
Ezetimibe48$1,425
Pravastatin Sodium82$1,363
Rosuvastatin Calcium160$1,272
Gabapentin75$1,265
Epinephrine13$1,229
Telmisartan26$1,155
Amlodipine Besylate191$973
Clobetasol Propionate12$965
Levothyroxine Sodium108$925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$107$50,35738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →